Free tool
FAERS Monitor: Arranon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021877 or its brand name (Arranon, Nelarabine). Reports on generic versions are filed under their own applications.
Reports
974
Serious
937
96% of reports
Hospitalization
329
Death reported
213
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia76
- drug ineffective67
- neuropathy peripheral63
- neurotoxicity61
- peripheral sensory neuropathy56
- sepsis56
- muscular weakness55
- off label use53
- myelopathy52
- neutropenia52
- guillain-barre syndrome42
- thrombocytopenia41
- gait disturbance39
- hypoaesthesia39
- peripheral motor neuropathy37
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 10 |
| 2007 | 13 |
| 2008 | 17 |
| 2009 | 24 |
| 2010 | 26 |
| 2011 | 26 |
| 2012 | 27 |
| 2013 | 73 |
| 2014 | 52 |
| 2015 | 39 |
| 2016 | 48 |
| 2017 | 64 |
| 2018 | 56 |
| 2019 | 29 |
| 2020 | 39 |
| 2021 | 35 |
| 2022 | 98 |
| 2023 | 77 |
| 2024 | 68 |
| 2025 | 116 |
| 2026 | 37 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,185 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelopathySignal | 52 | 607.9 | 464.8 | 30,060 |
| peripheral motor neuropathySignal | 37 | 585.9 | 425.3 | 20,470 |
| peripheral sensory neuropathySignal | 56 | 208.9 | 161.8 | 11,273 |
| guillain-barre syndromeSignal | 42 | 189.1 | 140.5 | 7,608 |
| neurotoxicitySignal | 61 | 75.4 | 59.1 | 4,395 |
| febrile neutropeniaSignal | 76 | 24.8 | 20.0 | 1,713 |
| neuropathy peripheralSignal | 63 | 14.3 | 11.3 | 770 |
| sepsisSignal | 56 | 10.8 | 8.4 | 493 |
| muscular weaknessSignal | 55 | 10.5 | 8.1 | 463 |
| neutropeniaSignal | 52 | 8.3 | 6.3 | 327 |
| thrombocytopeniaSignal | 41 | 7.9 | 5.9 | 242 |
| hypoaesthesiaSignal | 39 | 5.6 | 4.1 | 145 |
| gait disturbanceSignal | 39 | 4.4 | 3.2 | 100 |
| off label use | 53 | 1.3 | 1.0 | 4 |
| drug ineffective | 67 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.